The LONRF2 antibody is a tool used to detect and study the LONRF2 protein, a member of the LON protease family implicated in cellular protein quality control and ubiquitination processes. LONRF2 (LON peptidase N-terminal domain and RING finger protein 2) contains a conserved RING finger domain, characteristic of E3 ubiquitin ligases, and is involved in tagging misfolded or damaged proteins for degradation via the ubiquitin-proteasome system. While its exact biological roles remain under investigation, LONRF2 is thought to participate in maintaining protein homeostasis, regulating oxidative stress responses, and modulating cellular pathways linked to neurodegenerative diseases and cancer.
Antibodies targeting LONRF2 enable researchers to explore its expression, localization, and interactions in various tissues and disease models. These antibodies are widely used in techniques such as Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to elucidate its role in pathological conditions. For instance, studies suggest LONRF2 may influence neurotoxicity in Parkinson’s disease by interacting with α-synuclein aggregates or contribute to tumor progression through dysregulated protein turnover.
Despite its potential significance, research on LONRF2 is still emerging, with ongoing efforts to map its substrates, signaling networks, and therapeutic relevance. Commercial LONRF2 antibodies are available from multiple suppliers, often validated for specificity in human, mouse, or rat samples. Further functional studies, including knockout models, are needed to fully unravel its physiological and pathological mechanisms.